In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Payer Power: What Are The Future Implications For Life Science Companies Developing New Products?

How US Commercial Payers Will Manage Rapidly Increasing Drug Costs

Executive Summary

Payers cannot control the pricing of new products by biopharmaceutical companies, but their goal is to deliver quality health care in a cost-effective manner. Several payer medical directors representing over 100 million commercially insured members have shared their insights for managing the challenging US market – revealing their thoughts on drug pricing currently, and steps they plan to take in the next 3 to 5 years to better control rising costs.

You may also be interested in...



Sartans Recalled In UK As Further Impurity Is Confirmed

Certain batches of two angiotensin II receptor blockers, or sartans, are being recalled in the UK after an impurity that can potentially increase the risk of cancer over time was detected.

UK Regulator Eyes Expedited Process For Securing Full ICH Membership

The UK is on a mission to re-join the International Council for Harmonisation as a fully active member with voting rights.

Advanz Partners With Eisai For Zonisamide

Advanz has entered into an agreement with Eisai to acquire rights to its Zonegran zonisamide brand in Europe, the Middle East, Russia and Australia. Advanz said the move was “in keeping with our strategic growth plans” after the company was recently acquired by Nordic Capital in an $846m deal. 

Topics

Related Companies

UsernamePublicRestriction

Register

IV124195

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel